Chlamydia pneumoniae is the new third species of genus Chlamydia with one strain (serovar) called TWAR. It is proposed to investigate the epidemiology of several aspects of TWAR infection now poorly understood and shown to be of potential importance. These are TWAR infections in the elderly, in children in the tropics, during military training, in relation to asthma, and in coronary artery disease and other atherosclerosis. The technique used for these studies include microimmunofluorescence serology, isolation of the organism in HL cell culture and the polymerase chain reaction (PCR) to demonstrate TWAR specific DNA. The pathology and microbiology of TWAR infection in the lung will be studied in both human lung and with an experimental mouse model of pulmonary infection. The human lungs to be studied will include tissue from autopsies, both fresh and archival, and bronchioaleveolar lavage and bronchial brushing specimens from bronchoscopy. Latent and relapse infection will be sought. The techniques for these studies of lungs include those listed above, plus immunochemical staining of tissue sections utilizing TWAR specific monoclonal antibody (human tissue only), double-label immunofluorescent antibody stain, and in situ hybridization. Antibiotic treatment of C. pneumoniae infection, particularly directed at eradication of the organism from tissue, will be studied in the mouse model of TWAR pneumonia. A major thrust of the project is to identify, isolate, and produce specific antigens of C. pneumoniae using recombinant and synthetic techniques. Such antigens will be applied to simplified serology and development of vaccine for prevention of infection. The mouse model will be used for studies of prevention by immunization. The epidemiological studies will identify populations that can benefit from immunization.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI021885-10
Application #
2061640
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Project Start
1988-04-01
Project End
1998-03-31
Budget Start
1994-04-01
Budget End
1995-03-31
Support Year
10
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Washington
Department
Pathology
Type
Schools of Public Health
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Kuo, C C (1999) Pathologic manifestation of Chlamydial infection. Am Heart J 138:S496-9
Nochlin, D; Shaw, C M; Campbell, L A et al. (1999) Failure to detect Chlamydia pneumoniae in brain tissues of Alzheimer's disease. Neurology 53:1888
Grayston, J T (1999) Does Chlamydia pneumoniae cause atherosclerosis? Arch Surg 134:930-4
Moazed, T C; Kuo, C C; Grayston, J T et al. (1998) Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 177:1322-5
Wright, S W; Edwards, K M; Decker, M D et al. (1997) Prevalence of positive serology for acute Chlamydia pneumoniae infection in emergency department patients with persistent cough. Acad Emerg Med 4:179-83
Jackson, L A; Campbell, L A; Schmidt, R A et al. (1997) Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 150:1785-90
Moazed, T C; Kuo, C; Grayston, J T et al. (1997) Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 175:883-90
Jackson, L A; Campbell, L A; Kuo, C C et al. (1997) Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 176:292-5
Kuo, C C; Coulson, A S; Campbell, L A et al. (1997) Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg 26:29-31
Kuo, C C; Jackson, L A; Lee, A et al. (1996) In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 40:2669-70

Showing the most recent 10 out of 72 publications